Noven's Licensed CNS Drug Receives FDA's Tentative Approval
Posted on: Thursday, 27 December 2007, 09:00 CST
Noven has reported that the FDA has issued a tentative approval letter related to the new drug application for Stavzor in 125mg, 250mg and 500mg strengths.
The tentative approval relates to the use of Stavzor in the treatment of manic episodes associated with bipolar disorder, monotherapy and adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.
Based on receipt of the tentative approval letter and Noven's understanding of Depakote exclusivity, the company expects FDA final approval of Stavzor by the end of July 2008.
Robert Strauss, president, CEO & chairman of Noven, said: "Stavzor launch and production planning is underway in support of an expected 2008 launch through the Noven/JDS sales and marketing organization."
Source: Datamonitor
Related Articles
- Noven Announces 2008 Third Quarter Financial Results
- Noven Announces 2008 Second Quarter Financial Results
- Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
- Barr Receives Tentative Approval for Generic Drug
- FedEx Pilots' Union Leadership Approves Tentative Contract
- Road Projects Receive Tentative Approval
- Noven Announces FDA Approval of Daytrana(TM) Methylphenidate Transdermal System
- Budget OK'D in Preston: Raises Raise Issues for Some Office Holders
- Noven Provides Update on Developmental Fentanyl Patch
- Property Owners May See School Taxes Drop Higher Overall Property Values Allow District to Ease Taxpayers' Burden in the $155 Million Budget
 |
 |
User Comments (0)
RSS Feeds